MAIA reports positive efficacy results from Phase II trial for NSCLC

MAIA Biotechnology has reported positive initial efficacy results from its Phase II THIO-101 trial, involving ateganosine as a third-line treatment for patients with advanced NSCLC. Patients in Part C studies were administered ateganosine followed by cemiplimab on a 21-day cycle. THIO-101 is the first study to assess ateganosine’s anti-tumour activity followed by PD-(L)1 inhibition. Credit: afotostock / Shutterstock.com. MAIA Biotechnology has reported positive initial efficacy results from its Phase II THIO-101 trial, Part C, involving its lead candidate, ateganosine, as a third-line treatment for patients with advanced non-small cell lung cancer (NSCLC). Early data from the Part C studies report…

Source: Clinical Trials Arena